24 September 2025 - Australia’s drug regulator has approved the registration of an ­amyloid-reducing therapy for Alzheimer’s disease after twice rejecting it over safety concerns.

Lecanemab, also known as Leqembi, has now been cleared for use in some people with mild cognitive impairment because of early-stage Alzheimer’s disease. Supporters have welcomed the move, saying it is a significant step and provides patients with more options.

Read The Australian article